TARSUS PHARMACEUTICALS, INC. Interest Receivable, Current
TARSUS PHARMACEUTICALS, INC. (TARS) had Interest Receivable, Current of $178.00 thousand as of 2022-12-31, per its 10-K filed 2023-03-17.
Discontinued › Notes › Nontrade Receivables, Current
us-gaap:InterestReceivableCurrent · last filed 2023-03-17
- 2022-12-31: Interest Receivable, Current $178.00K.
- 2022-09-30: Interest Receivable, Current $198.00K.
- 2021-12-31: Interest Receivable, Current $2.00K.
| Period end | Interest Receivable, Current |
|---|---|
| 2022-12-31 | $178.00K 10-K · filed 2023-03-17 |
| 2022-09-30 | $198.00K 10-Q · filed 2022-11-09 |
| 2021-12-31 | $2.00K 10-K · filed 2023-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |